^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Epkinly (epcoritamab-bysp)

    i
    Other names: GEN-3013, DuoBody-CD3xCD20, Duobody-CD3-CD20, ABBV-GEN3013, ABBV-GMAB-3013, GEN3013
    Company:
    AbbVie, Genmab
    Drug class:
    CD20 inhibitor, CD3 agonist
    Related drugs:
    5d
    Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Suspended --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • Epkinly (epcoritamab-bysp)
    9d
    Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jun 2026 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    16d
    Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=43, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: Dec 2028 --> Oct 2029 | Initiation date: Dec 2026 --> Apr 2026 | Trial primary completion date: Dec 2028 --> Oct 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    26d
    REBEL: External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, University of Utah
    New P1 trial
    |
    Epkinly (epcoritamab-bysp) • Columvi (glofitamab-gxbm)
    1m
    HOVON 178 WM: Treatment of Waldenstroms macroglobulinemia with epcoritamab if the disease comes back during or after previous treatment (2025-522295-91-00)
    P1/2, N=28, Not yet recruiting, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting | N=14 --> 28
    Enrollment change
    |
    CD20 positive
    |
    Epkinly (epcoritamab-bysp)
    1m
    EPCORE DLBCL-4: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=379, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • Rituxan (rituximab) • lenalidomide • oxaliplatin • Epkinly (epcoritamab-bysp)
    1m
    ECLAT: A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, Memorial Sloan Kettering Cancer Center | N=27 --> 0 | Trial completion date: Aug 2028 --> Mar 2026 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2028 --> Mar 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD4 (CD4 Molecule)
    |
    lenalidomide • Epkinly (epcoritamab-bysp) • Monjuvi (tafasitamab-cxix)
    1m
    CLLRT2: A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation (2024-513445-37-00)
    P2/3, N=57, Not yet recruiting, University Of Cologne
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    2ms
    Successful Use of Epcoritamab in Refractory Diffuse Large B-Cell Lymphoma with Central Nervous System Involvement: A Case Report. (PubMed, Case Rep Oncol)
    However, epcoritamab induced a rapid systemic response along with partial neurological improvement. This case highlights the potential role of bispecific antibody therapy in refractory DLBCL with CNS involvement, an area of significant unmet clinical need.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Epkinly (epcoritamab-bysp) • methotrexate IV
    2ms
    CLLRT2: A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation (2024-513445-37-00)
    P2/3, N=41, Not yet recruiting, University Of Cologne
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    2ms
    Triple Infections With Campylobacter coli, Cytomegalovirus, and SARS-CoV-2 in a Lymphoma Patient Treated With Epcoritamab. (PubMed, Cureus)
    Chemoimmunotherapy for malignant lymphoma, including corticosteroids, rituximab (R), and Bruton's tyrosine kinase inhibitors, depletes normal lymphocytes and disrupts lymphocyte function...We treated a case of relapsed malignant lymphoma, infected with triple infections, Campylobacter coli, Cytomegalovirus, and SARS-CoV-2, during treatment with epcoritamab after standard chemoimmunotherapies, including R-cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), and R-bendamustine...His treatment for infections included remdesivir, meropenem, and ganciclovir...Epcoritamab can demonstrate long-standing B-cell depletion; however, a long-term influence on T cells is still elusive. This case suggested that we should pay special attention to patients with B-cell manipulating therapy including R, CAR-T, and BiTEs such as epcoritamab.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • bendamustine • Epkinly (epcoritamab-bysp)
    2ms
    Epcoritamab in Previously Treated WM (clinicaltrials.gov)
    P2, N=20, Recruiting, Gottfried von Keudell, MD PhD | Trial primary completion date: Oct 2025 --> Apr 2027
    Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Epkinly (epcoritamab-bysp)